324 related articles for article (PubMed ID: 33676314)
1. Novel thienopyrimidine analogues as potential metabotropic glutamate receptors inhibitors and anticancer activity: Synthesis, In-vitro, In-silico, and SAR approaches.
Khedr MA; Abu-Zied KM; Zaghary WA; Aly AS; Shouman DN; Haffez H
Bioorg Chem; 2021 Apr; 109():104729. PubMed ID: 33676314
[TBL] [Abstract][Full Text] [Related]
2. Synthesis, biological evaluation and molecular docking studies of novel thiopyrimidine analogue as apoptotic agent with potential anticancer activity.
Haffez H; Taha H; Rabie MA; Awad SM; Zohny YM
Bioorg Chem; 2020 Nov; 104():104249. PubMed ID: 32911199
[TBL] [Abstract][Full Text] [Related]
3. Design and synthesis of thienopyrimidine urea derivatives with potential cytotoxic and pro-apoptotic activity against breast cancer cell line MCF-7.
Abdelhaleem EF; Abdelhameid MK; Kassab AE; Kandeel MM
Eur J Med Chem; 2018 Jan; 143():1807-1825. PubMed ID: 29133058
[TBL] [Abstract][Full Text] [Related]
4. Thieno[2,3-d]pyrimidin-4(3H)-one Derivatives of Benzimidazole as Potential Anti- Breast Cancer (MDA-MB-231, MCF-7) Agents.
Dimov S; Mavrova AT; Yancheva D; Nikolova B; Tsoneva I
Anticancer Agents Med Chem; 2021; 21(11):1441-1450. PubMed ID: 32698751
[TBL] [Abstract][Full Text] [Related]
5. Novel thienopyrimidine derivatives as dual EGFR and VEGFR-2 inhibitors: design, synthesis, anticancer activity and effect on cell cycle profile.
Mghwary AE; Gedawy EM; Kamal AM; Abuel-Maaty SM
J Enzyme Inhib Med Chem; 2019 Dec; 34(1):838-852. PubMed ID: 30919701
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis and anticancer evaluation of thieno[2,3-d]pyrimidine derivatives as dual EGFR/HER2 inhibitors and apoptosis inducers.
Elmetwally SA; Saied KF; Eissa IH; Elkaeed EB
Bioorg Chem; 2019 Jul; 88():102944. PubMed ID: 31051400
[TBL] [Abstract][Full Text] [Related]
7. Biological Activity, Apoptotic Induction and Cell Cycle Arrest of New Hydrazonoyl Halides Derivatives.
Mohamed MF; Hassaneen HM; Elzayat EM; El-Hallouty SM; El-Manawaty M; Saleh FM; Mohamed Y; El-Zohiry D; Fahmy G; Abdelaal N; Hassanin N; Hossam N
Anticancer Agents Med Chem; 2019; 19(9):1141-1149. PubMed ID: 30843494
[TBL] [Abstract][Full Text] [Related]
8. Novel Pyrazolo[3,4-d]pyrimidines as Potential Cytotoxic Agents: Design, Synthesis, Molecular Docking and CDK2 Inhibition.
Maher M; Kassab AE; Zaher AF; Mahmoud Z
Anticancer Agents Med Chem; 2019; 19(11):1368-1381. PubMed ID: 31038080
[TBL] [Abstract][Full Text] [Related]
9. Pyrazolo[3,4-d]pyrimidine-based dual EGFR T790M/HER2 inhibitors: Design, synthesis, structure-activity relationship and biological activity as potential antitumor and anticonvulsant agents.
Lamie PF; El-Kalaawy AM; Abdel Latif NS; Rashed LA; Philoppes JN
Eur J Med Chem; 2021 Mar; 214():113222. PubMed ID: 33545637
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis, anticancer evaluation, molecular docking and cell cycle analysis of 3-methyl-4,7-dihydropyrazolo[1,5-a]pyrimidine derivatives as potent histone lysine demethylases (KDM) inhibitors and apoptosis inducers.
Metwally NH; Mohamed MS; Ragb EA
Bioorg Chem; 2019 Jul; 88():102929. PubMed ID: 31015179
[TBL] [Abstract][Full Text] [Related]
11. New pyranopyrazole based derivatives: Design, synthesis, and biological evaluation as potential topoisomerase II inhibitors, apoptotic inducers, and antiproliferative agents.
Sobh EA; Kassab AE; El-Khouly EA; S A Hassan M
Bioorg Chem; 2024 Mar; 144():107158. PubMed ID: 38301427
[TBL] [Abstract][Full Text] [Related]
12. Novel pyrazolo[3,4-d]pyrimidines: design, synthesis, anticancer activity, dual EGFR/ErbB2 receptor tyrosine kinases inhibitory activity, effects on cell cycle profile and caspase-3-mediated apoptosis.
Maher M; Kassab AE; Zaher AF; Mahmoud Z
J Enzyme Inhib Med Chem; 2019 Dec; 34(1):532-546. PubMed ID: 30688116
[TBL] [Abstract][Full Text] [Related]
13. Cytotoxic and Apoptotic Effects of Novel Pyrrolo[2,3-d]Pyrimidine Derivatives Containing Urea Moieties on Cancer Cell Lines.
Kilic-Kurt Z; Bakar-Ates F; Karakas B; Kütük Ö
Anticancer Agents Med Chem; 2018; 18(9):1303-1312. PubMed ID: 29866023
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis, biological evaluation, and modeling studies of novel conformationally-restricted analogues of sorafenib as selective kinase-inhibitory antiproliferative agents against hepatocellular carcinoma cells.
Sbenati RM; Zaraei SO; El-Gamal MI; Anbar HS; Tarazi H; Zoghbor MM; Mohamood NA; Khakpour MM; Zaher DM; Omar HA; Alach NN; Shehata MK; El-Gamal R
Eur J Med Chem; 2021 Jan; 210():113081. PubMed ID: 33310290
[TBL] [Abstract][Full Text] [Related]
15. 2-Anilinopyrimidine derivatives: Design, synthesis, in vitro anti-proliferative activity, EGFR and ARO inhibitory activity, cell cycle analysis and molecular docking study.
AboulWafa OM; Daabees HMG; Badawi WA
Bioorg Chem; 2020 Jun; 99():103798. PubMed ID: 32247112
[TBL] [Abstract][Full Text] [Related]
16. Design, green synthesis, molecular docking and anticancer evaluations of diazepam bearing sulfonamide moieties as VEGFR-2 inhibitors.
Saleh NM; El-Gaby MSA; El-Adl K; Abd El-Sattar NEA
Bioorg Chem; 2020 Nov; 104():104350. PubMed ID: 33142416
[TBL] [Abstract][Full Text] [Related]
17. Novel imidazolone derivatives as potential dual inhibitors of checkpoint kinases 1 and 2: Design, synthesis, cytotoxicity evaluation, and mechanistic insights.
Sheta YS; Sarg MT; Abdulrahman FG; Nossier ES; Husseiny EM
Bioorg Chem; 2024 Aug; 149():107471. PubMed ID: 38823311
[TBL] [Abstract][Full Text] [Related]
18. Synthesis, anticancer effect and molecular modeling of new thiazolylpyrazolyl coumarin derivatives targeting VEGFR-2 kinase and inducing cell cycle arrest and apoptosis.
Mohamed TK; Batran RZ; Elseginy SA; Ali MM; Mahmoud AE
Bioorg Chem; 2019 Apr; 85():253-273. PubMed ID: 30641320
[TBL] [Abstract][Full Text] [Related]
19. Design, Synthesis, In Vitro Anti-cancer Activity, ADMET Profile and Molecular Docking of Novel Triazolo[3,4-a]phthalazine Derivatives Targeting VEGFR-2 Enzyme.
El-Helby AA; Sakr H; Ayyad RRA; El-Adl K; Ali MM; Khedr F
Anticancer Agents Med Chem; 2018; 18(8):1184-1196. PubMed ID: 29651967
[TBL] [Abstract][Full Text] [Related]
20. New fused pyrimidine derivatives with anticancer activity: Synthesis, topoisomerase II inhibition, apoptotic inducing activity and molecular modeling study.
Nemr MTM; AboulMagd AM
Bioorg Chem; 2020 Oct; 103():104134. PubMed ID: 32750610
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]